AAAAAA

   
Results: 1-25 | 26-50 | 51-75 | 76-100 | >>
Results: 1-25/118
LIQUID-CHROMATOGRAPHIC DETERMINATION OF IRINOTECAN AND 3 MAJOR METABOLITES IN HUMAN PLASMA, URINE AND FECES
Authors: SPARREBOOM A DEBRUIJN P DEJONGE MJA LOOS WJ STOTER G VERWEIJ J NOOTER K
Citation: A. Sparreboom et al., LIQUID-CHROMATOGRAPHIC DETERMINATION OF IRINOTECAN AND 3 MAJOR METABOLITES IN HUMAN PLASMA, URINE AND FECES, Journal of chromatography B. Biomedical sciences and applications, 712(1-2), 1998, pp. 225-235
DETERMINATION OF PACLITAXEL IN HUMAN PLASMA USING SINGLE SOLVENT-EXTRACTION PRIOR TO ISOCRATIC REVERSED-PHASE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH ULTRAVIOLET DETECTION
Authors: SPARREBOOM A DEBRUIJN P NOOTER K LOOS WJ STOTER G VERWEIJ J
Citation: A. Sparreboom et al., DETERMINATION OF PACLITAXEL IN HUMAN PLASMA USING SINGLE SOLVENT-EXTRACTION PRIOR TO ISOCRATIC REVERSED-PHASE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH ULTRAVIOLET DETECTION, Journal of chromatography B. Biomedical sciences and applications, 705(1), 1998, pp. 159-164
DISPOSITION OF CREMOPHOR EL IN HUMANS LIMITS THE POTENTIAL FOR MODULATION OF THE MULTIDRUG-RESISTANCE PHENOTYPE IN-VIVO
Authors: SPARREBOOM A VERWEIJ J VANDERBURG MEL LOOS WJ BROUWER E VIGANO L LOCATELLI A DEVOS AI NOOTER K STOTER G GIANNI L
Citation: A. Sparreboom et al., DISPOSITION OF CREMOPHOR EL IN HUMANS LIMITS THE POTENTIAL FOR MODULATION OF THE MULTIDRUG-RESISTANCE PHENOTYPE IN-VIVO, Clinical cancer research, 4(8), 1998, pp. 1937-1942
IRINOTECAN (CPT-11) METABOLISM AND DISPOSITION IN CANCER-PATIENTS
Authors: SPARREBOOM A DEJONGE MJA DEBRUIJN P BROUWER E NOOTER K LOOS WJ VANALPHEN RJ MATHIJSSEN RHJ STOTER G VERWEIJ J
Citation: A. Sparreboom et al., IRINOTECAN (CPT-11) METABOLISM AND DISPOSITION IN CANCER-PATIENTS, Clinical cancer research, 4(11), 1998, pp. 2747-2754
IN-VIVO MODEL SYSTEMS IN P-GLYCOPROTEIN-MEDIATED MULTIDRUG-RESISTANCE
Authors: VANDEVRIE W MARQUET RL STOTER G DEBRUIJN EA EGGERMONT AMM
Citation: W. Vandevrie et al., IN-VIVO MODEL SYSTEMS IN P-GLYCOPROTEIN-MEDIATED MULTIDRUG-RESISTANCE, Critical reviews in clinical laboratory sciences, 35(1), 1998, pp. 1-57
EXPRESSION OF THE MULTIDRUG-RESISTANCE PROTEIN (MRP) IN SQUAMOUS-CELLCARCINOMA OF THE ESOPHAGUS AND RESPONSE TO PREOPERATIVE CHEMOTHERAPY
Authors: NOOTER K KOK T BOSMAN FT VANWINGERDEN KE STOTER G
Citation: K. Nooter et al., EXPRESSION OF THE MULTIDRUG-RESISTANCE PROTEIN (MRP) IN SQUAMOUS-CELLCARCINOMA OF THE ESOPHAGUS AND RESPONSE TO PREOPERATIVE CHEMOTHERAPY, European journal of cancer, 34(1), 1998, pp. 81-86
CORTICOSTEROID CO-MEDICATION DOES NOT REDUCE THE INCIDENCE AND SEVERITY OF NEUROTOXICITY INDUCED BY DOCETAXEL
Authors: PRONK LC HILKENS PHE VANDENBENT MJ VANPUTTEN WLJ STOTER G VERWEIJ J
Citation: Lc. Pronk et al., CORTICOSTEROID CO-MEDICATION DOES NOT REDUCE THE INCIDENCE AND SEVERITY OF NEUROTOXICITY INDUCED BY DOCETAXEL, Anti-cancer drugs, 9(9), 1998, pp. 759-764
CISPLATIN - DNA-ADDUCTS AND PROTEIN-BOUND PLATINUM IN BLOOD OF TESTICULAR CANCER-PATIENTS
Authors: BOFFETTA P FICHTINGERSCHEPMAN AMJ WEIDERPASS E VANDIJKKNIJNENBURG HCM STOTER G VANOOSTEROM AT KEIZER HJ FOSSA SD KALDOR J ROY P
Citation: P. Boffetta et al., CISPLATIN - DNA-ADDUCTS AND PROTEIN-BOUND PLATINUM IN BLOOD OF TESTICULAR CANCER-PATIENTS, Anti-cancer drugs, 9(2), 1998, pp. 125-129
LIQUID-CHROMATOGRAPHIC DETERMINATION OF IRINOTECAN (CPT-11) AND ITS MAJOR METABOLITES IN HUMAN PLASMA, URINE AND FECES
Authors: SPARREBOOM A DEBRUIJN P DEJONGE MJA LOOS WJ NOOTER K STOTER G VERWEIJ J
Citation: A. Sparreboom et al., LIQUID-CHROMATOGRAPHIC DETERMINATION OF IRINOTECAN (CPT-11) AND ITS MAJOR METABOLITES IN HUMAN PLASMA, URINE AND FECES, Annals of oncology, 9, 1998, pp. 219-219
PHASE-I STUDY OF WEEKLY CISPLATIN (P) AND 4-WEEKLY OR WEEKLY TAXOL (T) - A HIGHLY-ACTIVE THERAPY IN FIRST AND 2ND LINE ADVANCED EPITHELIAL OVARIAN-CANCER (OC)
Authors: VANDERBURG MEL DEWIT R STOTER G VERWEIJ J
Citation: Mel. Vanderburg et al., PHASE-I STUDY OF WEEKLY CISPLATIN (P) AND 4-WEEKLY OR WEEKLY TAXOL (T) - A HIGHLY-ACTIVE THERAPY IN FIRST AND 2ND LINE ADVANCED EPITHELIAL OVARIAN-CANCER (OC), Annals of oncology, 9, 1998, pp. 376-376
A RAPID COLORIMETRIC DYE-BINDING MICROASSAY FOR QUANTITATION OF THE PACLITAXEL VEHICLE CREMOPHOR EL
Authors: SPARREBOOM A LOOS WJ BROUWER E NOOTER K STOTER G VERWEIJ J
Citation: A. Sparreboom et al., A RAPID COLORIMETRIC DYE-BINDING MICROASSAY FOR QUANTITATION OF THE PACLITAXEL VEHICLE CREMOPHOR EL, Annals of oncology, 9, 1998, pp. 503-503
CLINICAL PHARMACOKINETICS OF DOXORUBICIN IN COMBINATION WITH GF120918, A POTENT INHIBITOR OF MDR1 P-GLYCOPROTEIN
Authors: SPARREBOOM A PLANTING AST JEWELL RC PAUL EM WISSEL PS DEBRUIJN P NOOTER K STOTER G VERWEIJ J
Citation: A. Sparreboom et al., CLINICAL PHARMACOKINETICS OF DOXORUBICIN IN COMBINATION WITH GF120918, A POTENT INHIBITOR OF MDR1 P-GLYCOPROTEIN, Annals of oncology, 9, 1998, pp. 550-550
DISPOSITION OF CREMOPHOR EL IN HUMANS LIMITS THE POTENTIAL FOR MODULATION OF THE MULTIDRUG-RESISTANCE PHENOTYPE IN-VIVO
Authors: SPARREBOOM A VERWEIJ J VANDERBURG MEL LOOS WJ VIGANO L LOCATELLI A NOOTER K STOTER G GIANNI L
Citation: A. Sparreboom et al., DISPOSITION OF CREMOPHOR EL IN HUMANS LIMITS THE POTENTIAL FOR MODULATION OF THE MULTIDRUG-RESISTANCE PHENOTYPE IN-VIVO, Annals of oncology, 9, 1998, pp. 551-551
A PHASE I II STUDY OF THE SAFETY OF AUTOLOGOUS GENE MODIFIED T-LYMPHOCYTES IN PATIENTS WITH METASTATIC RENAL-CANCER/
Authors: BOLHUIS RLH STOTER G LAMERS CHJ WILLEMSEN RA GRATAMA JW WEIJTENS MEM
Citation: Rlh. Bolhuis et al., A PHASE I II STUDY OF THE SAFETY OF AUTOLOGOUS GENE MODIFIED T-LYMPHOCYTES IN PATIENTS WITH METASTATIC RENAL-CANCER/, The FASEB journal, 12(4), 1998, pp. 1679-1679
EXPRESSION OF P53, P21 WAF/CIP, BCL-2, BAX, BCL-X, AND BAK IN RADIATION-INDUCED APOPTOSIS IN TESTICULAR GERM-CELL TUMOR LINES/
Authors: BURGER H NOOTER K BOERSMA AWM KORTLAND CJ VANDENBERG AP STOTER G
Citation: H. Burger et al., EXPRESSION OF P53, P21 WAF/CIP, BCL-2, BAX, BCL-X, AND BAK IN RADIATION-INDUCED APOPTOSIS IN TESTICULAR GERM-CELL TUMOR LINES/, International journal of radiation oncology, biology, physics, 41(2), 1998, pp. 415-424
SYNERGISTIC CYTOTOXICITY OF CISPLATIN AND TOPOTECAN OR SN-38 IN A PANEL OF 8 SOLID-TUMOR CELL-LINES IN-VITRO
Authors: MA JG MALIEPAARD M NOTTER K BOERSMA AWM VERWEIJ J STOTER G SCHELLENS JHM
Citation: Jg. Ma et al., SYNERGISTIC CYTOTOXICITY OF CISPLATIN AND TOPOTECAN OR SN-38 IN A PANEL OF 8 SOLID-TUMOR CELL-LINES IN-VITRO, Cancer chemotherapy and pharmacology, 41(4), 1998, pp. 307-316
THE EFFECT OF DEXAMETHASONE ON THE UPTAKE OF CISPLATIN IN 9L GLIOMA AND THE AREA OF BRAIN AROUND TUMOR
Authors: STRAATHOF CSM VANDENBENT MJ MA J SCHMITZ PIM KROS JM STOTER G VECHT CJ SCHELLENS JHM
Citation: Csm. Straathof et al., THE EFFECT OF DEXAMETHASONE ON THE UPTAKE OF CISPLATIN IN 9L GLIOMA AND THE AREA OF BRAIN AROUND TUMOR, Journal of neuro-oncology, 37(1), 1998, pp. 1-8
4 CYCLES OF BEP VS 4 CYCLES OF VIP IN PATIENTS WITH INTERMEDIATE-PROGNOSIS METASTATIC TESTICULAR NON SEMINOMA - A RANDOMIZED STUDY OF THE EORTC GENITOURINARY TRACT CANCER COOPERATIVE GROUP
Authors: DEWIT R STOTER G SLEIJFER D NEIJT JP HUININK WWT DEPRIJCK L COLLETTE L SYLVESTER R
Citation: R. Dewit et al., 4 CYCLES OF BEP VS 4 CYCLES OF VIP IN PATIENTS WITH INTERMEDIATE-PROGNOSIS METASTATIC TESTICULAR NON SEMINOMA - A RANDOMIZED STUDY OF THE EORTC GENITOURINARY TRACT CANCER COOPERATIVE GROUP, British Journal of Cancer, 78(6), 1998, pp. 828-832
DOCETAXEL (TAXOTERE) - AN ACTIVE AGENT IN METASTATIC UROTHELIAL CANCER - RESULTS OF A PHASE-II STUDY IN NON-CHEMOTHERAPY-PRETREATED PATIENTS
Authors: DEWIT R KRUIT WHJ STOTER G DEBOER M KERGER J VERWEIJ J
Citation: R. Dewit et al., DOCETAXEL (TAXOTERE) - AN ACTIVE AGENT IN METASTATIC UROTHELIAL CANCER - RESULTS OF A PHASE-II STUDY IN NON-CHEMOTHERAPY-PRETREATED PATIENTS, British Journal of Cancer, 78(10), 1998, pp. 1342-1345
SERUM ALPHA-FETOPROTEIN SURGE AFTER THE INITIATION OF CHEMOTHERAPY FOR NONSEMINOMATOUS TESTICULAR CANCER HAS AN ADVERSE PROGNOSTIC-SIGNIFICANCE
Authors: DEWIT R COLLETTE L SYLVESTER R DEMULDER PHM SLEIJFER DT HUININK WWT KAYE SB VANOOSTEROM AT BOVEN E STOTER G
Citation: R. Dewit et al., SERUM ALPHA-FETOPROTEIN SURGE AFTER THE INITIATION OF CHEMOTHERAPY FOR NONSEMINOMATOUS TESTICULAR CANCER HAS AN ADVERSE PROGNOSTIC-SIGNIFICANCE, British Journal of Cancer, 78(10), 1998, pp. 1350-1355
A PHASE-I PHASE-II STUDY OF MULTICYCLIC DOSE-INTENSIVE CHEMOTHERAPY SUPPORTED WITH G-CSF, OR G-CSF AND HEMATOPOIETIC PROGENITOR CELLS IN WHOLE-BLOOD, IN 2 CONSECUTIVE COHORTS OF PATIENTS/
Authors: DEWIT R KRUIT WHJ LAMERS CHJ VANTVEER MB LUYTEN AA VANBEURDEN V HARTEVELD M PLANTING AST SCHMITZ PIM STOTER G BOLHUIS RLH VERWEIJ J
Citation: R. Dewit et al., A PHASE-I PHASE-II STUDY OF MULTICYCLIC DOSE-INTENSIVE CHEMOTHERAPY SUPPORTED WITH G-CSF, OR G-CSF AND HEMATOPOIETIC PROGENITOR CELLS IN WHOLE-BLOOD, IN 2 CONSECUTIVE COHORTS OF PATIENTS/, British Journal of Cancer, 77(12), 1998, pp. 2363-2366
EXPRESSION OF P53, BCL-2 AND BAX IN CISPLATIN-INDUCED APOPTOSIS IN TESTICULAR GERM-CELL TUMOR-CELL LINES
Authors: BURGER H NOOTER K BOERSMA AWM KORTLAND CJ STOTER G
Citation: H. Burger et al., EXPRESSION OF P53, BCL-2 AND BAX IN CISPLATIN-INDUCED APOPTOSIS IN TESTICULAR GERM-CELL TUMOR-CELL LINES, British Journal of Cancer, 77(10), 1998, pp. 1562-1567
REDUCED CELLULAR ACCUMULATION OF TOPOTECAN - A NOVEL MECHANISM OF RESISTANCE IN A HUMAN OVARIAN-CANCER CELL-LINE
Authors: MA J MALIEPAARD M NOOTER K LOOS WJ KOLKER HJ VERWEIJ J STOTER G SCHELLENS JHM
Citation: J. Ma et al., REDUCED CELLULAR ACCUMULATION OF TOPOTECAN - A NOVEL MECHANISM OF RESISTANCE IN A HUMAN OVARIAN-CANCER CELL-LINE, British Journal of Cancer, 77(10), 1998, pp. 1645-1652
LINEARIZED COLORIMETRIC ASSAY FOR CREMOPHOR EL - APPLICATION TO PHARMACOKINETICS AFTER 1-HOUR PACLITAXEL INFUSIONS
Authors: BROUWER E VERWEIJ J HAUNS B LOOS WJ NOOTER E MROSS K STOTER G SPARREBOOM A
Citation: E. Brouwer et al., LINEARIZED COLORIMETRIC ASSAY FOR CREMOPHOR EL - APPLICATION TO PHARMACOKINETICS AFTER 1-HOUR PACLITAXEL INFUSIONS, Analytical biochemistry (Print), 261(2), 1998, pp. 198-202
QUANTITATION OF CREMOPHOR EL IN HUMAN PLASMA SAMPLES USING A COLORIMETRIC DYE-BINDING MICROASSAY
Authors: SPARREBOOM A LOOS WJ VERWEIJ J DEVOS AI VANDERBURG MEL STOTER G NOOTER K
Citation: A. Sparreboom et al., QUANTITATION OF CREMOPHOR EL IN HUMAN PLASMA SAMPLES USING A COLORIMETRIC DYE-BINDING MICROASSAY, Analytical biochemistry, 255(2), 1998, pp. 171-175
Risultati: 1-25 | 26-50 | 51-75 | 76-100 | >>